Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 2/20 | 0.31 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.31 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468671 | 1.00 | SCN5A (0.33) | SCN5ASCN9AP2RX7ALDH3A1KDM4E | |
| SCHEMBL4473545 | 1.00 | SCN5A (0.33) | SCN5ASCN9AP2RX7ALDH3A1KDM4E | |
| SCHEMBL4471269 | 0.94 | P2RX7 (0.31) | P2RX7ALDH3A1KDM4EHPGDCCR4 | |
| SCHEMBL4468598 | 0.94 | P2RX7 (0.31) | P2RX7ALDH3A1KDM4EHPGDCCR4 | |
| SCHEMBL4472859 | 0.94 | P2RX7 (0.31) | P2RX7ALDH3A1KDM4EHPGDCCR4 | |
| SCHEMBL4473439 | 0.92 | SCN5A (0.35) | SCN5ASCN9AP2RX7ALDH3A1 | |
| SCHEMBL4473435 | 0.92 | SCN5A (0.35) | SCN5ASCN9AP2RX7ALDH3A1 | |
| SCHEMBL4483952 | 0.92 | SCN5A (0.35) | SCN5ASCN9AP2RX7ALDH3A1 | |
| SCHEMBL4474105 | 0.90 | P2RX7 (0.37) | P2RX7ALDH3A1KDM4EHPGDCCR4 | |
| SCHEMBL4462641 | 0.88 | ALDH1A1 (0.36) | SCN5ASCN9AALDH3A1KDM4ENOTCH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078428-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | claimed |
| EP-1528923-B1 | N-((3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)ACETYL)GUANIDINE DERIVATIVES AS NHE1-INHIBITORS FOR THE TREATMENT OF INFARCTION AND ANGINA PECTORIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-03 | — | — | EP | claimed |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUSCHLAND GMBH (DE) | 2004-03-11 | — | — | US | claimed |
| US-7589117-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-7078428-B2 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUSCHLAND GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148880-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | SCN5A 149/4885SCN9A 1749/4885P2RX7 690/4885 |
| US-20040048916-A1 | Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | TNNI3, NDUFB3, NDUFB11 | SCN5A 181/4885SCN9A 1811/4885P2RX7 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.